What drugs target D-Ala-D-Ala peptidoglycan precursor?

7+ drugs target D-Ala-D-Ala peptidoglycan precursor, including Vancomycin - model-based dosing regimen, Vancomycin CI, Vancomycin (POC), Administration of Vancomycin, Vancomycin IV.

What drug classes act on D-Ala-D-Ala peptidoglycan precursor?

Drug classes acting on D-Ala-D-Ala peptidoglycan precursor include Glycopeptide antibiotic.

D-Ala-D-Ala peptidoglycan precursor — Drug Target

7 drugs 6 marketed 1 in Phase 3

All drugs that target D-Ala-D-Ala peptidoglycan precursor — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

Glycopeptide antibiotic

Marketed (6)

Vancomycin - model-based dosing regimen · Murdoch Childrens Research Institute · Glycopeptide antibiotic · Infectious Disease
Vancomycin inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, preventing cross-linking and causing cell wall disruption.
Vancomycin CI · Wake Forest University Health Sciences · Glycopeptide antibiotic · Infectious Disease
Vancomycin inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, preventing cross-linking and causing cell wall rupture.
Vancomycin (POC) · University of Maryland, Baltimore · Glycopeptide antibiotic · Infectious Disease
Vancomycin inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, preventing cross-linking and causing cell wall rupture.
Administration of Vancomycin · University of Colorado, Denver · Glycopeptide antibiotic · Infectious Disease
Vancomycin inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptide precursors and preventing peptidoglycan cross-linking.
Vancomycin IV · Debiopharm International SA · Glycopeptide antibiotic · Infectious Disease
Vancomycin inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, preventing cross-linking and causing cell wall disruption.
Vancomycin II · Wake Forest University Health Sciences · Glycopeptide antibiotic · Infectious Disease
Vancomycin II inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, preventing cross-linking and causing cell wall disruption.

Phase 3 pipeline (1)

Comparator: vancomycin · Merck Sharp & Dohme LLC · Glycopeptide antibiotic · Infectious Disease
Vancomycin is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors.